Compare Stocks

→ Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRN Amarin	$0.88 +2.0%	$1.00	$0.65 ▼ $1.49	$362.75M	1.98	2.00 million shs	760,481 shs
OCGN Ocugen	$1.25 +0.8%	$1.24	$0.35 ▼ $2.11	$321.66M	3.51	8.11 million shs	6.86 million shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRN Amarin	+0.74%	-5.76%	+0.70%	-28.45%	-35.87%
OCGN Ocugen	-6.06%	-22.01%	-24.39%	+132.34%	+57.74%

Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (Ad)

“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.

See how you can invest alongside him

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMRN Amarin	0.2092 of 5 stars	1.9	3.0	0.0	0.0	0.0	0.0	0.6
OCGN Ocugen	0.8943 of 5 stars	3.5	1.0	0.0	0.0	2.9	0.0	0.0

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMRN Amarin	1.75	Reduce	$1.08	22.65% Upside
OCGN Ocugen	3.00	Buy	$4.67	273.33% Upside

Current Analyst Ratings

Latest OCGN and AMRN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/22/2024	OCGN Ocugen	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.00 ➝ $5.00
4/3/2024	OCGN Ocugen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
2/22/2024	OCGN Ocugen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
1/24/2024	OCGN Ocugen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$5.00 ➝ $7.00

(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMRN Amarin	$306.91M	1.18	N/A	N/A	$1.35 per share	0.65
OCGN Ocugen	$6.04M	53.26	N/A	N/A	$0.16 per share	7.81

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMRN Amarin	-$59.11M	-$0.14	N/A	N/A	N/A	-19.26%	-10.47%	-6.97%	5/1/2024 (Confirmed)
OCGN Ocugen	-$63.08M	-$0.27	N/A	N/A	N/A	N/A	-102.97%	-77.75%	5/3/2024 (Estimated)

Latest OCGN and AMRN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/1/2024	N/A	AMRN Amarin	-$0.0350	N/A	+$0.0350	N/A	N/A	N/A
2/29/2024	Q4 2023	AMRN Amarin	-$0.05	-$0.01	+$0.04	-$0.01	$72.46 million	$74.71 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMRN Amarin	N/A	N/A	N/A	N/A	N/A
OCGN Ocugen	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMRN Amarin	N/A	2.80	1.80
OCGN Ocugen	0.07	2.51	2.51

Ownership

Institutional Ownership

Company	Institutional Ownership
AMRN Amarin	22.25%
OCGN Ocugen	10.27%

Insider Ownership

Company	Insider Ownership
AMRN Amarin	1.96%
OCGN Ocugen	3.48%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
AMRN Amarin	275	410.67 million	402.62 million	Optionable
OCGN Ocugen	84	257.33 million	248.37 million	Optionable

OCGN and AMRN Headlines

Source	Headline
	IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm prnewswire.com - April 23 at 11:30 AM
	Ocugen (NASDAQ:OCGN) Price Target Increased to $5.00 by Analysts at Chardan Capital americanbankingnews.com - April 23 at 3:32 AM
	Ocugen (NASDAQ:OCGN) Given New $5.00 Price Target at Chardan Capital marketbeat.com - April 22 at 8:29 AM
	Key Takeaways From Ocugen Analyst Ratings markets.businessinsider.com - April 22 at 8:19 AM
	DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm accesswire.com - April 22 at 7:00 AM
	SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen markets.businessinsider.com - April 21 at 10:14 AM
	DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm accesswire.com - April 21 at 7:00 AM
	SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Ocugen, Inc. - OCGN prnewswire.com - April 20 at 11:00 AM
	Ocugen: Two Gene Therapy Data Readouts In 2024 To Drive Value seekingalpha.com - April 19 at 8:04 PM
	OCGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ocugen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! prnewswire.com - April 19 at 12:00 PM
	Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy globenewswire.com - April 19 at 7:13 AM
	DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm accesswire.com - April 19 at 7:00 AM
	Ocugen stock jumps after $175M securities filing msn.com - April 18 at 9:05 AM
	SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm accesswire.com - April 18 at 9:00 AM
	Ocugen, Inc. (OCGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings stockhouse.com - April 18 at 12:44 AM
	ROSEN, THE FIRST FILING FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN prnewswire.com - April 17 at 11:00 PM
	INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm markets.businessinsider.com - April 17 at 2:44 PM
	IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm prnewswire.com - April 17 at 1:51 PM
	Ocugen (OCGN) Price Target Decreased by 15.79% to 5.44 msn.com - April 17 at 9:43 AM
	OCGN Stock Earnings: Ocugen Beats EPS for Q4 2023 msn.com - April 17 at 12:32 AM
	3 Standout Penny Stocks to Watch This April msn.com - April 16 at 2:32 PM
	Short Interest in Ocugen, Inc. (NASDAQ:OCGN) Grows By 22.8% marketbeat.com - April 15 at 5:09 PM
	SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm accesswire.com - April 15 at 12:00 PM
	SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm prnewswire.com - April 15 at 9:00 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Amarin

NASDAQ:AMRN

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Ocugen

NASDAQ:OCGN

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. It has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial